肿瘤浸润淋巴细胞CD3<sup>+</sup>、CD4<sup>+</sup>T细胞联合IL-17检测对非小细胞肺癌患者预后的预测价值

doi:10.3969/j.issn.1671-7171.2024.07.014

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1450 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨肿瘤浸润淋巴细胞CD3⁺、CD4⁺T细胞联合白细胞介素-17(IL-17)检测对非小细胞肺癌(NSCLC)患者预后的预测价值。【方法】本院收治的132例行肺癌根治术的NSCLC患者,术后随访3年。分析影响患者预后的因素及生存状况,比较无病生存与复发患者CD3⁺、CD4⁺T细胞及IL-17表达水平及其与患者预后的关系。【结果】无病生存组患者的CD3⁺、CD4⁺T细胞计数均高于复发组(P<0.05),IL-17的阳性表达率低于复发组(P<0.05)。多因素Logistic回归分析显示,肿瘤分期、CD3⁺和CD4⁺T细胞计数、IL-17阳性是NSCLC患者治疗后无病生存的影响因素(P<0.05)。受试者工作特征(ROC)曲线分析显示,CD3⁺和CD4⁺T细胞、IL-17及三者联合预测NSCLC患者无病生存的灵敏度分别为72.22%、75.93%、70.37%、81.48%,特异度分别为73.44%、71.88%、70.31%、90.63%。CD3⁺和CD4⁺T细胞高表达组患者的无病生存曲线均优于低表达组(P<0.05),IL-17阴性表达组的无病生存曲线优于阳性表达组(P<0.05)。【结论】CD3⁺、CD4⁺T细胞及IL-17与NSCLC预后有关,三者联合预测患者预后的效能良好,且CD3⁺、CD4⁺T细胞低表达者及IL-17阳性表达者预后不良的风险较高。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	刘庆丰

关键词 ：癌,非小细胞肺, 淋巴细胞,肿瘤浸润, 白细胞介素17, 预后

Abstract：【Objective】 To investigate the prognostic value of combined detection of tumor-infiltrating CD3⁺ and CD4⁺ T cells and interleukin-17 (IL-17) in non-small cell lung cancer (NSCLC). 【Methods】 A total of 132 NSCLC patients who underwent radical lung cancer surgery in our hospital were followed up for 3 years postoperatively. Factors affecting patient prognosis and survival status were analyzed, and the expression levels of CD3⁺ and CD4⁺ T cells and IL-17 were compared between disease-free and recurrent patients, along with their relationship to prognosis. 【Results】 The counts of CD3⁺ and CD4⁺ T cells in the disease-free group were higher than those in the recurrence group (P<0.05), and the positive expression rate of IL-17 in the disease-free group was lower than that in the recurrence group (P<0.05). Multivariate logistic regression analysis showed that tumor staging, CD3⁺ and CD4⁺ cell counts, and IL-17 positivity were factors affecting disease-free survival in NSCLC patients (P<0.05). Receiver operating characteristic (ROC) curve analysis indicated that the sensitivity of CD3⁺ T cells, CD4⁺ T cells, IL-17, and their combination in predicting disease-free survival in NSCLC patients were 72.22%, 75.93%, 70.37%, and 81.48%, respectively, and the specificities were 73.44%, 71.88%, 70.31%, and 90.63%, respectively. The disease-free survival curves for patients with high expression of CD3⁺ and CD4⁺ T cells were better than those for patients with low expression (P<0.05), and the disease-free survival curve for the IL-17 negative expression group was better than that for the IL-17 positive expression group (P<0.05). 【Conclusion】 The CD3⁺ T cells, CD4⁺ T cells, and IL-17 are associated with the prognosis of NSCLC, and the combined prediction of these three markers has good prognostic value. Patients with low expression of CD3⁺ and CD4⁺ T cells and positive expression of IL-17 have a higher risk of poor prognosis.

Key words： Carcinoma, Non-Small-Cell Lung Lymphocytes, Tumor-Infiltrating Interleukin-17 Prognosis

收稿日期: 2023-12-27

中图分类号:

R734.2

引用本文:

刘庆丰. 肿瘤浸润淋巴细胞CD3⁺、CD4⁺T细胞联合IL-17检测对非小细胞肺癌患者预后的预测价值[J]. 医学临床研究, 2024, 41(7): 1009-1012.
LIU Qingfeng. Prognostic Value of Combined Detection of Tumor-Infiltrating CD3⁺ and CD4⁺ T Cells and IL-17 in Non-Small Cell Lung Cancer. JOURNAL OF CLINICAL RESEARCH, 2024, 41(7): 1009-1012.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2024.07.014 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2024/V41/I7/1009

[1] CHAFT J E, RIMNER A, WEDER W, et al. Evolution of systemic therapy for stages Ⅰ-Ⅲ non-metastatic non-small-cell lung cancer[J].Nat Rev Clin Oncol,2021, 18(9):547-557.
[2] JOHN A, YANG B, SHAH R. Clinical impact of adherence to NCCN guidelines for biomarker testing and first-line treatment in advanced non-small cell lung cancer (aNSCLC) using real-world electronic health record data[J].Adv Ther,2021, 38(3):1552-1566.
[3] CHIOU S H, TSENG D, REUBEN A, et al. Global analysis of shared T cell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery[J].Immunity,2021, 54(3):586-602.
[4] KAMIMAKI C, KOBAYASHI N, HIRATA M, et al. T-cell response to phytohemagglutinin in the interferon-γ release assay as a potential biomarker for the response to immune checkpoint inhibitors in patients with non-small cell lung cancer[J].Thorac Cancer,2021, 12(11):1726-1734.
[5] SANMAMED M F, NIE X, DESAI S S, et al. A Burned-out CD8⁺ t-cell subset expands in the tumor microenvironment and curbs cancer immunotherapy[J].Cancer Discov,2021, 11(7):1700-1715.
[6] 中华医学会, 中华医学会肿瘤学分会,中华医学会杂志社. 中华医学会肺癌临床诊疗指南(2018版)[J].中华肿瘤杂志, 2018, 40(12):935-964.
[7] ZAAROUR R F, PRASAD P, VENKATESH G H, et al. Waterpipe smoke condensate influences epithelial to mesenchymal transition and interferes with the cytotoxic immune response in non-small cell lung cancer cell lines[J].Oncol Rep,2021, 45(3):879-890.
[8] JOHNSON A M, BOLAND J M, WROBEL J, et al. Cancer cell-specific major histocompatibility complex Ⅱ expression as a determinant of the immune infiltrate organization and function in the nsclc tumor microenvironment[J].J Thorac Oncol,2021, 16(10):1694-1704.
[9] QU J J, MEI Q H, CHEN L J, et al. Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives[J].Cancer Immunol Immunother,2021, 70(3):619-631.
[10] CROSBY D A, GLOVER L E, BRENNAN E P, et al. Dysregulation of the interleukin-17A pathway in endometrial tissue from women with unexplained infertility affects pregnancy outcome following assisted reproductive treatment[J].Hum Reprod,2020, 35(8):1875-1888.
[11] ABOUSHOUSHA T, EMAD M, RIZK G, et al. IL-4, IL-17 and CD163 immunoexpression and IL-6 gene polymorphism in chronic hepatitis C patients and associated hepatocellular carcinoma[J].Asian Pac J Cancer Prev,2021, 22(4):1105-1113.
[12] CONFORTI F, PALA L, PAGAN E, et al. Sex-based dimorphism of anticancer immune response and molecular mechanisms of immune evasion[J].Clin Cancer Res,2021, 27(15):4311-4324.
[13] TANG K H, LI S, KHODADADI-JAMAYRAN A, et al. Combined inhibition of SHP2 and CXCR1/2 promotes antitumor T-cell response in NSCLC[J].Cancer Discov,2022, 12(1):47-61.
[14] CREELAN B C, WANG C, TEER J K, et al. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial[J].Nat Med,2021, 27(8):1410-1418.